"Pyridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
| Descriptor ID |
D011725
|
| MeSH Number(s) |
D03.383.725
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridines".
Below are MeSH descriptors whose meaning is more specific than "Pyridines".
This graph shows the total number of publications written about "Pyridines" by people in this website by year, and whether "Pyridines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 2 | 3 |
| 1999 | 1 | 1 | 2 |
| 2000 | 4 | 1 | 5 |
| 2001 | 1 | 5 | 6 |
| 2002 | 2 | 0 | 2 |
| 2003 | 0 | 2 | 2 |
| 2004 | 1 | 4 | 5 |
| 2005 | 1 | 6 | 7 |
| 2006 | 4 | 0 | 4 |
| 2007 | 4 | 4 | 8 |
| 2008 | 5 | 2 | 7 |
| 2009 | 8 | 3 | 11 |
| 2010 | 12 | 6 | 18 |
| 2011 | 10 | 2 | 12 |
| 2012 | 7 | 5 | 12 |
| 2013 | 5 | 4 | 9 |
| 2014 | 6 | 4 | 10 |
| 2015 | 7 | 5 | 12 |
| 2016 | 8 | 6 | 14 |
| 2017 | 4 | 6 | 10 |
| 2018 | 5 | 7 | 12 |
| 2019 | 1 | 6 | 7 |
| 2020 | 5 | 6 | 11 |
| 2021 | 6 | 7 | 13 |
| 2022 | 0 | 8 | 8 |
| 2023 | 2 | 4 | 6 |
| 2024 | 7 | 5 | 12 |
| 2025 | 0 | 1 | 1 |
| 2026 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyridines" by people in Profiles.
-
Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2026 Jul; 10(7):e2600456.
-
Impact of Fostamatinib on Inflammatory Biomarkers in Hospitalized Patients With COVID-19. Crit Care Explor. 2026 Jul 01; 8(7):e1405.
-
Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice. J Diabetes Investig. 2026 Apr; 17(4):567-575.
-
Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting. Future Oncol. 2025 Sep; 21(21):2823-2833.
-
Dual Targeting EZH2 and Histone Deacetylases in Human Uterine Sarcoma Cells Under Both 2D and 3D Culture Conditions. J Cell Mol Med. 2025 06; 29(11):e70626.
-
NEPA (Netupitant/Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial. Cancer Med. 2025 Apr; 14(7):e70549.
-
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer. J Oncol Pharm Pract. 2026 Jun; 32(4):641-647.
-
Fostamatinib for Hospitalized Adults With COVID-19 and Hypoxemia: A Randomized Clinical Trial. JAMA Netw Open. 2024 12 02; 7(12):e2448215.
-
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2025 02; 10(2):138-153.
-
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 10; 8:e2400477.